Author name: DrugChatter

Walk into any pharmaceutical brand team meeting in 2025 and you’ll hear the same anxieties: biosimilar erosion, payer step therapy, […]

The pharmacovigilance team at a mid-size specialty pharma company discovered the problem during a routine brand audit. Patients searching for

Drug companies spend billions crafting brand narratives. AI is rewriting them in real time — and most manufacturers have no

A scan of patient-generated questions reveals a striking pattern: confusion rarely centers on what drugs do—it centers on how they

How artificial intelligence is tracking, shaping, and sometimes undermining pharmaceutical brand strategy — and what drug companies need to do

A scan of hundreds of real-world questions on DrugChatter reveals a consistent pattern: patients are not just asking what a

In online drug discussions, some of the most routine-sounding questions can mask a more serious issue: patients delaying appropriate medical

Patients aren’t just looking up side effects anymore—they’re making real-time treatment decisions based on fragmented, crowd-sourced advice. A review of

Across hundreds of patient-driven questions on DrugChatter, a clear pattern emerges: drug interactions are less about classic pharmacology errors and

There used to be a reliable playbook. You identified the twenty physicians who shaped prescribing behavior in a given therapeutic

Across DrugChatter, a clear pattern emerges: patients are increasingly comfortable with switching to generics—but far less confident that “generic =

Across thousands of patient-facing Q&A threads on DrugChatter, a consistent pattern emerges: adherence to common medications is often shaped less